Clinical Trials Logo

Pancreatic Cancer clinical trials

View clinical trials related to Pancreatic Cancer.

Filter by:

NCT ID: NCT00583271 Completed - Pancreatic Cancer Clinical Trials

A Prospective Study of EUS Guided Celiac Block

Start date: June 2002
Phase: N/A
Study type: Observational

The purpose of this prospective study is to measure the clinical effectiveness of EUS-guided CB in subjects, 50 who have chronic pancreatitis and 50 who have pancreatic cancer, that are already undergoing celiac block for clinical reasons.

NCT ID: NCT00582699 Completed - Pancreatic Cancer Clinical Trials

Depression, Cytokines and Pancreatic Cancer

Start date: November 2005
Phase: N/A
Study type: Observational

The purpose of this study is to measure certain specific chemicals in your blood, produced by the body in response to a stress, such as having pancreatic cancer. These chemicals are called "cytokines" and the researchers doing this study want to look at the role they may play in developing depression.

NCT ID: NCT00582647 Active, not recruiting - Pancreatic Cancer Clinical Trials

Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract

Start date: March 2000
Phase:
Study type: Observational

Doctors at Memorial Sloan Kettering Cancer Center and at other institutions study normal and cancer cells. To study these cells we need to have human tissue, body fluids, and blood. The patient will be having or have had a procedure to remove tissue. The doctors would like to use some of this tissue. The doctors will use it for laboratory studies on the causes, prevention, diagnosis and treatment of sarcoma, gastrointestinal or other intra-abdominal cancers. They will only use extra tissue left over after all needed testing has been done. They would also like to study components of the immune blood cells and blood serum (the liquid portion of the blood). In some patients they will take a blood sample before the tissue or body fluid is removed, usually at the same time that other routine pre-procedure blood tests are drawn. If thet need more blood, it will be drawn when the patient is seeing the doctor anyway. We will not draw more than 50cc (4-5 tablespoons) at any one time. With the patient's permission, thet may also send a small portion of the blood and/or a sample of the tissue to a repository at the National Cancer Institute. This will be used to identify special proteins in the blood or tissue that may be useful for diagnosing cancer. Information about the treatment and the response to treatment may be linked to the tissue specimens obtained. This information may be important for the research studies that will be done on the tissue, body fluid and blood specimens. All of this information will be kept in strictest confidence; they will use it only for biomedical research. The patient's name will not be used in any report.

NCT ID: NCT00581815 Completed - Breast Cancer Clinical Trials

Spectroscopy With Surface Coils and Decoupling

Start date: February 1997
Phase: Phase 1
Study type: Interventional

The purpose of this study is to obtain chemical information from part of your body without a biopsy. This is done using a technique called magnetic resonance spectroscopy (MRS) which is similar to magnetic resonance imaging (MRI) except that signals are detected from the chemicals (spectroscopy) naturally present in your body using radio waves. To receive this information from your body, small loops of wire (surface coils), placed near the tissue of interest, may be used to more effectively detect signals that come from the chemicals in your body. The investigators may use a second radio channel simultaneously, which will allow us to obtain greater chemical information (decoupling). The results may also help us to understand how this study can be used to help other patients with your condition.

NCT ID: NCT00580021 Withdrawn - Breast Cancer Clinical Trials

Clinical Outcomes in Hereditary Cancer

Start date: January 2006
Phase: N/A
Study type: Observational

Compare the clinical characteristics and post-surgical outcomes (overall survival)of pancreatic cancer patients of Ashkenazi descent with or without germline founder mutations in BRCA1 or BRCA2 . Compare the clinical characteristics and outcomes (time to progression) of breast cancer patients of Ashkenazi descent with or without germline founder mutations in BRCA1 or BRCA2 receiving paclitaxel chemotherapy for metastatic disease.

NCT ID: NCT00578279 Completed - Pancreatic Cancer Clinical Trials

Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study

Start date: March 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to obtain preliminary safety and efficacy data after endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) in patients with locally advanced or unresectable pancreatic adenocarcinoma. Hypotheses: 1. Increased amounts of alcohol used in EUS-CPN is safe and more efficacious in improving pain relief in patients with locally advanced or unresectable pancreatic adenocarcinoma. 2. Effective pain relief obtained from EUS-CPN will be related to better quality of life (QOL)

NCT ID: NCT00577564 Completed - Pancreatic Cancer Clinical Trials

EUS-CPN: A Retrospective Review

Start date: July 2006
Phase: N/A
Study type: Observational

The purpose of this retrospective study is to measure the safety of EUS-CPN in patients that have undergone this procedure in the last decade.

NCT ID: NCT00576940 Completed - Pancreatic Cancer Clinical Trials

Standard and Immunostimulating Enteral Nutrition in Surgical Patients

ImmuniEteral
Start date: June 2004
Phase: Phase 4
Study type: Interventional

The aim of the study was to assess the clinical effect of immunomodulating enteral nutrition in patients undergoing resection for gastrointestinal cancer. 196 subjects were randomly assigned into two study groups: standard and immunostimulating. The study failed to demonstrate any clear advantage of routine postoperative immunonutrition in patients undergoing elective upper gastrointestinal surgery

NCT ID: NCT00570713 Completed - Pancreatic Cancer Clinical Trials

An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer

Start date: December 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the activity of MORAb-009 when added to a standard regimen of gemcitabine in patients with previously untreated unresectable stage 3 or 4 pancreatic cancer.

NCT ID: NCT00569387 Completed - Pancreatic Cancer Clinical Trials

Vaccine Study for Surgically Resected Pancreatic Cancer

Start date: December 2007
Phase: Phase 2
Study type: Interventional

To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with chemotherapy and chemoradiation.